GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Operating Margin %

Ablynx NV (XBRU:ABLXS) Operating Margin % : -138.66% (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ablynx NV's Operating Income for the six months ended in Dec. 2017 was €-28.98 Mil. Ablynx NV's Revenue for the six months ended in Dec. 2017 was €20.90 Mil. Therefore, Ablynx NV's Operating Margin % for the quarter that ended in Dec. 2017 was -138.66%.

Good Sign:

Ablynx NV operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Ablynx NV's Operating Margin % or its related term are showing as below:

XBRU:ABLXS' s Operating Margin % Range Over the Past 10 Years
Min: -226.54   Med: -78.48   Max: -21.62
Current: -96.71


XBRU:ABLXS's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -161.26 vs XBRU:ABLXS: -96.71

Ablynx NV's 5-Year Average Operating Margin % Growth Rate was 4.90% per year.

Ablynx NV's Operating Income for the six months ended in Dec. 2017 was €-28.98 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2017 was €-53.73 Mil.

Warning Sign:

Ablynx NV had operating loss over the past 3 years.


Ablynx NV Operating Margin % Historical Data

The historical data trend for Ablynx NV's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Operating Margin % Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.35 -30.81 -21.62 -33.19 -96.71

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.30 -3.81 -82.48 -71.42 -138.66

Competitive Comparison of Ablynx NV's Operating Margin %

For the Biotechnology subindustry, Ablynx NV's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Operating Margin % falls into.



Ablynx NV Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ablynx NV's Operating Margin % for the fiscal year that ended in Dec. 2017 is calculated as

Operating Margin %=Operating Income (A: Dec. 2017 ) / Revenue (A: Dec. 2017 )
=-53.733 / 55.562
=-96.71 %

Ablynx NV's Operating Margin % for the quarter that ended in Dec. 2017 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2017 ) / Revenue (Q: Dec. 2017 )
=-28.976 / 20.897
=-138.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ablynx NV Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (XBRU:ABLXS) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines